1. Home
  2. NKGN vs IMNN Comparison

NKGN vs IMNN Comparison

Compare NKGN & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • IMNN
  • Stock Information
  • Founded
  • NKGN 2017
  • IMNN 1982
  • Country
  • NKGN United States
  • IMNN United States
  • Employees
  • NKGN N/A
  • IMNN N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • IMNN Biotechnology: Pharmaceutical Preparations
  • Sector
  • NKGN Health Care
  • IMNN Health Care
  • Exchange
  • NKGN Nasdaq
  • IMNN Nasdaq
  • Market Cap
  • NKGN 14.1M
  • IMNN 15.1M
  • IPO Year
  • NKGN N/A
  • IMNN 1985
  • Fundamental
  • Price
  • NKGN $0.28
  • IMNN $1.02
  • Analyst Decision
  • NKGN
  • IMNN Strong Buy
  • Analyst Count
  • NKGN 0
  • IMNN 2
  • Target Price
  • NKGN N/A
  • IMNN $21.50
  • AVG Volume (30 Days)
  • NKGN 360.3K
  • IMNN 227.1K
  • Earning Date
  • NKGN 11-12-2024
  • IMNN 11-12-2024
  • Dividend Yield
  • NKGN N/A
  • IMNN N/A
  • EPS Growth
  • NKGN N/A
  • IMNN N/A
  • EPS
  • NKGN N/A
  • IMNN N/A
  • Revenue
  • NKGN N/A
  • IMNN N/A
  • Revenue This Year
  • NKGN N/A
  • IMNN N/A
  • Revenue Next Year
  • NKGN N/A
  • IMNN N/A
  • P/E Ratio
  • NKGN N/A
  • IMNN N/A
  • Revenue Growth
  • NKGN N/A
  • IMNN N/A
  • 52 Week Low
  • NKGN $0.27
  • IMNN $0.48
  • 52 Week High
  • NKGN $5.10
  • IMNN $3.65
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 23.41
  • IMNN 45.77
  • Support Level
  • NKGN $0.36
  • IMNN $0.99
  • Resistance Level
  • NKGN $0.44
  • IMNN $1.08
  • Average True Range (ATR)
  • NKGN 0.04
  • IMNN 0.05
  • MACD
  • NKGN 0.00
  • IMNN 0.00
  • Stochastic Oscillator
  • NKGN 5.04
  • IMNN 33.33

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About IMNN Imunon Inc.

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Share on Social Networks: